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TABLE 1
Age, sex and laboratory results in four patients with RA and
concomitant HCV infection
HCV RNA
Pa tien.t Age Sex IgM RF Serum Synovial fluid
1 65 M + negative negative
2 67 M + positive negative
3 57 F -------- negative negative
4 33 F -------- negative positive (?)
Emeryville, CA, USA). Informed consent was obtained 
from all patients.
In three patients, HCV infection was community
it occurred after bloodacquired and in the 
transfusions. Two patients had consistently negative 
results both on serum and SF. One patient had 
consistently positive in the serum on four 
occasions (26.09 to 61.35 x 105 copies), whereas all 
three SF specimens were negative. In the fourth patient, 
HCV RNA was not detected in three different tests in 
the serum, but was present at the low concentration of 
5.92 x 105 copies in 1/3 SF specimens. HCV RNA was 
searched for in an arthroscopic biopsy o f  the SM by 
PCR with a negative result. Her disease was classified 
as Still’s disease, although the criteria for RA were also 
fulfilled. The patient had complained of arthritis since 
age 4 after smallpox vaccination. She had a remission 
at age 12, but later arthritis recurred with high spiking 
fever, severe anaemia, leucocytosis, pericarditis, and 
hepato- and splenomegaly. IgM rheumatoid factor 
(RF), ANA, anti-DNA and anti-ENA antibodies were 
negative. Interestingly, arthritis recurred a few years 
after the blood transfusions that most probably caused 
HCV infection.
In our experience, HCV did not show a tropism for 
the SM, despite the inflammation-related increase in 
permeability and vascularization, since even the 
patient with consistently positive tests in the serum
had no amounts of HCV RNA in
simultaneously aspirated SF samples. Moreover, the 
only positive test in the SF was not confirmed when 
the SM was evaluated. The diagnosis of HCV infection 
was made on the basis of positive ELISA and Western 
blot tests, and should not have been influenced by the
possible interference of IgM RF [6] or by 
concentrations of IgG [7]. Our data indicate the need 
for further studies on the role of the SM as a site for 
HCV persistence, and on SF analysis for viral RNA as 
a tool for differentiating RA and concomitant HCV 
infection from HCV-associated arthritis.
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Does Application of Radiographic Contrast Medium 
in Radiation Synovectomy Influence the Stability
of Yttrium-90 Colloid?
S ir — Radiation synovectomy is a well-established 
method of non-surgical synovectomy for chronic 
inflammatory arthritis [1-5]. It is carried out by an 
intra-articular (i.a.) injection o f  a radiopharmaceutical. 
It is necessary to ensure that the needle is positioned 
correctly in the joint space before injecting the 
radiopharmaceutical. This is to prevent the spread of 
radioactive material in the adjacent joint structures. 
Radiographic contrast medium can help to confirm the 
correct position of the needle in the joint, and can 
provide information about the spread of the radio­
nuclide in the joint space and adjacent bursae. For that 
aim, 1 ml of radiographic contrast is 
Radiographic contrast medium is especially used when 
there is only a small amount o f  effusion, as we often
villonodular synovitis [2] and in 
haemophilic haemarthrosis [6].
Some radiographic contrast media contain chelating 
compounds e.g. ethylenediaminetetra-acetate (EDTA). 
In the information sheet of the European Association 
of Nuclear Medicine (EANM), entitled ‘Radionuclide 
therapy: from palliation to cure’, it is reported that 
yttrium-90 (Y-90) colloid has an 
chelates (e.g. EDTA, which is used in iodine contrast
saw m
to some
may lead to a separation of 
radionuclide from the colloid and hence, because of
biodistribution intracavitary a d m i n i s -
tration, add to the bone marrow radiation dose [7].
So, the Y-90 EDTA complex can migrate into the 
blood circulation and be cleared by the kidneys. It may 
give undesirable radiation exposure of the whole body
a decreased therapeutic 
joint. We have not found 
literature on this phenomenon.
in the 
in the
We have examined the influence of
radiographic contrast medium on the biodistribution 
of Y-90 colloid injected in the knee joint. A controlled
Y-90comparative trial was carried out 
colloid and radiographic contrast medium Omnipaque 
(containing EDTA), Y-90 colloid and radiographic 
contrast medium Urografine (without EDTA), and
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Y-90 colloid with saline. The injections in the knee joint 
were followed by collection of the urine for 48 h and 
the radioactivity in the urine was measured.
Fifteen patients with an active chronic synovitis of 
the knee joint, which persisted after adequate treatment 
with anti-inflammatory drugs and i.a. corticosteroid
. Patients who 
both knees
. All
* r  i)
were trea with Y-90
111 s
patients had given informed consent, 
work conforms to
design o f  the
an i.a.
aining 0.1 mg EDTA, a second group
i.a. 1 ml Urografine 60% 
(Scheding) without EDTA and a control group o f  five
i.a. 1 each
an i.a. injection o f  185 MBq (5 mCi) 
citrate colloid (CIS bio international).
Y-90 colloid treatment, the following 
inflammatory activity variables of the knee joint were 
scored: tenderness, swelling, effusion and warmth on a 
four-point scale (0 =  absent, 1 =  slight, 2 =  moderate, 
3 =  severe). Furthermore, the ESR, the CRP, serum
and an X-ray of the knee joint were
X-rays were scored according to 
Larsen et at. [8]. The method for radiation synovec 
tomy has been described before [2, 3]. Briefly, 185 MBq 
Y-90 colloid were diluted in the vial up to 3 ml with
With the
performed.
tn ? 11* i*»♦#*i
patient
• lateral ¿
inserted into the synovial cavity i 
drained as completely as possible. Using a three-way 
tap, I of one of
hi
saline.
was
M 4*
a or 1 ml of 
185 MBq Y-
w i
a w n,
1 ml of
to the injection site and the
'e
twice
o re ini mo in full extension with a
bandage and/or a splint. The patient was 
to bed for 3 days.#
The urine of each patient was collected for 48 h. The 
total volume of each urine sample was determined and 
4 ml o f  each urine sample were used lor counting the 
radioactivity. Five microlitres of the solution of the 
injected doses were used as a standard and mixed with 
4 ml o f  blank urine. Also 4 ml o f  blank urine were
. To each urine sample o f  4 ml, 16 ml of  
scintillation solvent were added (Hionic Fluor Pack-
ard). The /¿-radiation o f  the Y- was in a
scintillation counter for 10 min. Calculation of
urine was performed
n n
percentage Y-90 m 
follows: “0 r  t h e i n urine [(/f/4)
X (C Ä)|/[(300Ü/5) x (.V ™ B)\ x 100, where A is
me of a urine sa e, C  is count
sample in e.p.rn., lì is the count of
i urine 
blank urine
sample in c.p.m. and S  is the count of the standard in 
c.p.m.
TABLE I
Nature and dose o f  radiographic contrast medium and urine 
radioactivity after Y-90 colloid measured as a percentage o f  the dose
administered in the knee joint
No. o f Radiographic contrast Radioactivity in urine
patients medium (mean ±  s .d .)
5 Oranipaque 1 ml 3.0 ±  1.8
5 Urografine 1 ml 3.0 ±  3.7
5 Saline 1 ml 3.1 ±  3.6
Quality control of three batches of Y-90 citrate
by chromatographycolloid was 
(Whatman 3 in acetone).
About 3% of the radioactivity administered into the 
joint was found in the 48 h urine sample (Table I). No  
differences in radioactivity counts were found between 
the three patient groups. There was no correlation
radioactivity in the urine and the 
inflammatory activity variables of the knee joints, such 
as tenderness, swelling, effusion, warmth, ESR and 
CRP. Serum creatinine was normal. No relationship 
was found between the radiological score [8] and the 
amount of radioactivity in the urine. Our radiochemi­
cal quality control showed a purity of Y-90 colloid of  
>99% .
In this study, no significant differences in radioac­
tivity excreted in the urine were found between three 
groups of patients treated with radiosynovectomy for 
a knee joint synovitis, whether or not a contrast 
medium, with or without EDTA, was added. Although 
on theoretical grounds one
"s or
joint and 
small
such
could be determined. There was also no 
between the inflammatory activity para- 
radiological score [8] of the treated knee 
radioactivity excreted in the urine. In this
of we cannot confirm the
in the EANM information sheet that for 
radiation synovectomy simultaneous administration of 
Y-90 colloid i.a. and iodine contrast media containing 
EDTA should be avoided.
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Re: Rheumatology in Israel
S ir — We have read with interest the International 
Letter ‘Rheumatology in Israel’ by Ehrenfeld et al. 
{British Journal of Rheumatology 1996;35:778-80).
Y our readers may be interested to learn of the 
important part played by British rheumatology in 
the development of rheumatology in Israel. The 
Rheumatology Department of the Rambam Medical 
Centre in Haifa, which opened its doors in 1974, was 
firmly established in the best traditions of Taplow, 
G u y ’s and the Kennedy where Professors Yehuda 
Scharf and Menahem Nahir (neither mentioned in 
Ehrenfeld article) received their specialist training in 
the 1970s. The Rambam unit remains, to this day, 
only designated univen rheumatology in-pi 
unit in Israel, having 12 beds (not 18 as reported in
dedicated for treatment of
diseases.
It was from •e that the first president of
fledgling Israel Society o f  Rheumatology was elected in
1984, that leading to
heavily resisted recognition of the speciality was waged,
that the curriculum of the Board in
Rheumatology was developed and where, until 1994, 
all qualifying examinations for the boards were held.
the years, an impressive, modern and popular 
service has been built up spanning rheumatology in the
sense, and matched by a commensurate 
programme of wide-ranging clinical and laboratory 
research (of which, contrary to what is stated in the 
report, AIDS research plays no part).
O f  particular importance to patient care in this unit 
has been, firstly, the introduction of the rheumatology 
nurse practitioner (based on the Leeds model) and, 
secondly, a uniquely close collaboration with their two 
British-trained rheumatological surgical colleagues, 
Professors Daniel Reis and Michael Besser. The most
came when Ms
Whitelock, from the R N H R D  in Bath, acted as 
external adviser on a scheme to develop a much-needed 
hydrotherapy pool, which opened last year.
The Rambam Rheumatology Unit has a
distinguished international reputation. The list of 
rheumatological world leaders who have contributed to 
its academic programme reads like an international 
‘W ho’s W ho’!
R. G r a h a m e , L. E . G l y n n
of Rheuma Guy's & St
Hospital Trust, St Thomas Street, London SEI 9RT
Accepted 18 >r 1996
Erythrocyte Sedimentation Rate (ESR) at Presentation 
is a Prognostic Indicator for Duration of Treatment in
Polymyalgia Rheumatica (PMR)
S ir— Dolan et al. [1] have compared ESRs in PMR 
patients still on prednisolone after 24 months with 
ESRs in those off prednisolone at 24 months. They 
describe a higher pre-treatment ESR and higher ESRs 
at 12 and 24 months in the group who were still on 
prednisolone after 24 months. However, they state that 
the prednisolone dose was reduced ‘according to 
disease activity and ESR’. This would create a 
‘self-fulfilling prophecy’ whereby patients with higher 
ESRs on treatment would be continued on higher doses 
of prednisolone for longer. This, in turn, raises the 
possibility that the apparent association o f  pre-treat- 
ment ESR and duration o f  prednisolone treatment is 
due not to true prediction of disease activity, but purely 
to prediction o f  later ESR levels regardless of clinical 
disease activity. In other words, are individuals who 
tend to run higher ESRs in health likely to have the
ESRs at presentation of inflammatory disease
We
PMR
I c at presentation, and in whom relapse was
diagnosed clinically without reference to ESR. 
cohort is, therefore, a valid group in which to examine 
usefulness o f  ESR at presentation as a prognostic 
:ator for the duration of treatment in PMR. 
cohort has been described previo 
44 patients 40 have now
[2], and of those 
followed either until
months or
40
patients, 29 were female and the median age was 71.5 
(range 51-87) yr; 25 had pure.  PMR
itis (GCA) and nine had 
sv-nrovcn GCA. Median ESR i
Six had
-----  r—  i
46 (range 7-112). Twenty-six patients suffered at least
one clinical relapse and duration of
re t
treatment was 34.5 months (range 12 to > 48  months).
and ESR during disease 
on treatment did show weak correlations
treatment (r„ =  0.229 and 0.297,
did not reach statistical 
0.261 and 0.149) in this group of 26. 
convincingly rule out a spurious 
association of pre-treatment ESR and duration of
